<DOC>
	<DOC>NCT00290563</DOC>
	<brief_summary>This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.</brief_summary>
	<brief_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>Patients with predominantly urge incontinence overactive bladder episodes Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia Lower urinary tract symptoms associated with benign prostatic hypertrophy Active or current Urinary Tract Infections (UTIs) Surgery to correct prolapsed uterus or stress incontinence</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>